Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.5280
-0.0030 (-0.56%)
At close: Aug 13, 2025, 4:00 PM
0.5410
+0.0130 (2.46%)
Pre-market: Aug 14, 2025, 8:39 AM EDT
RANI Employees
As of December 31, 2024, Rani Therapeutics Holdings had 106 total employees, including 105 full-time and 1 part-time employees. The number of employees decreased by 34 or -24.29% compared to the previous year.
Employees
106
Change (1Y)
-34
Growth (1Y)
-24.29%
Revenue / Employee
$11,321
Profits / Employee
-$280,057
Market Cap
37.95M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 106 | -34 | -24.29% |
Dec 31, 2023 | 140 | -23 | -14.11% |
Dec 31, 2022 | 163 | 49 | 42.98% |
Dec 31, 2021 | 114 | 43 | 60.56% |
Dec 31, 2020 | 71 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RANI News
- 6 days ago - Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering - GlobeNewsWire
- 4 weeks ago - Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery - GlobeNewsWire
- 3 months ago - Rani Therapeutics Announces Research Agreement with Chugai - GlobeNewsWire
- 3 months ago - Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 4 months ago - Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - GlobeNewsWire
- 5 months ago - Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - GlobeNewsWire